Blockade of Bv8 enhanced the efficacy of weekly gemcitabine treatment in terms of reversing these effects and increasing mice survival, indicating that approaches targeting Bv8 could be exploited to prevent chemotherapy-induced MDSCs mobilization in pancreatic cancer. Here, PROK2 is linked to familial pancreatic carcinoma.